Christopher Bunker

Company: Alamar Biosciences Inc.

Job title: VP, Biopharma Bus. Dev.

Seminars:

NULISA CNS Disease Biomarker Platform – The Only High-Plex, High Sensitivity Platform for Investigation of Biomarkers of Neurodegenerative Diseases & Treatment Response 9:30 am

NULISA™ combines ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis. The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies. NULISA enables the unique ability to translate discoveries based on broad profiling into single and low-plex biomarker assays on the same…Read more

day: Conference Day One AM